U.S. stocks ended the week mixed after news of fresh conflict between Russia and Ukraine.» Read More
Amgen Inc. rose$. 15 or. 1 percent, to $126.47. Biogen Idec rose $3.01 or. 9 percent, to $327.97. Celgene Corp. rose$. 22 or. 2 percent, to $86.66.
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Amgen Inc. rose$. 37 or. 3 percent, to $127.32. Biogen Idec fell $3.71 or 1.1 percent, to $320.34. Celgene Corp. rose$. 37 or. 4 percent, to $86.88.
Amgen Inc. rose$. 14 or. 1 percent, to $127.09. Biogen Idec fell $2.24 or. 7 percent, to $321.81. Celgene Corp. rose$. 51 or. 6 percent, to $87.02.
Amgen Inc. rose$. 33 or. 3 percent, to $127.28. Biogen Idec fell $1.84 or. 6 percent, to $322.21. Celgene Corp. rose$. 11 or. 1 percent, to $86.62.
Amgen Inc. rose $1.20 or 1.0 percent, to $126.95. Biogen Idec rose $3.45 or 1.1 percent, to $324.05. Celgene Corp. rose $1.29 or 1.5 percent, to $86.51.
Amgen Inc. rose$. 68 or. 5 percent, to $126.43. Biogen Idec rose $2.73 or. 9 percent, to $323.33. Celgene Corp. rose$. 75 or. 9 percent, to $85.97.
Amgen Inc. rose$. 24 or. 2 percent, to $125.99. Biogen Idec rose $2.04 or. 6 percent, to $322.64. Celgene Corp. rose$. 42 or. 5 percent, to $85.64.
Cramer likes to review the S&P 500’s Daily Action Charts in an effort to find stocks that could work higher.
Aug 1- Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc..
July 30- U.S. health insurer Humana Inc reported a lower profit owing to higher costs on Wednesday, as mounting concerns about increased medical spending drove health insurance industry shares lower for a second straight day.
July 30- U.S. health insurer Humana Inc said on Wednesday that second-quarter profit fell due to investments in the exchanges created under President Barack Obama's healthcare reform law as well as costly new hepatitis C drug treatments. Humana said membership growth and a lower share count due to stock buybacks had helped offset some of the new costs.
July 29- Aetna Inc, the third-largest U.S. health insurer, reported a rise in medical costs on Tuesday, raising investor concerns that a long run of low growth in such costs might be ending and pushing shares in the industry lower.
A new hepatitis drug could be significant for Arrowhead Research, CEO Chris Anzalone says.
NEW YORK, July 29- With some of Wall Street's more volatile names set to report in the next couple of days, traders who bet on big swings in shares are hoping to see moves more like Facebook than Netflix. Netflix, along with Gilead Sciences and several other stocks famous for their sharp gyrations, were unusually calm following their latest quarterly reports.
Many so-called momentum stocks have rebounded as economic data have been mixed and volatility remained low. Financial Times reports.
LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.
The "Fast Money" traders share their final trades of the day.
July 24- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.
Some of the names on the move ahead of the open.